Miraluma

   
Google
 
Web NewDrugInformation.com

Miraluma


Drug - Miraluma
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Technetium Tc-99m Sestamibi Kit
Multiple ingredients are in alphabetical order.

Strength - N/A
The potency of the active ingredient(s), Technetium Tc-99m Sestamibi Kit. May repeat for multiple part products.

Applicant - BRISTOL MYERS SQUIBB
The firm name holding legal responsibility for Miraluma. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 019785
The FDA assigned number to Miraluma. Format is nnnnnn.

Product Number - 003
The FDA assigned number to identify Miraluma. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - May 23, 1997
The date Miraluma was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Miraluma. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Miraluma is in. Format is RX, OTC, DISCN.

Applicant Full Name - Bristol Myers Squibb Pharma Co
The full name of the firm holding legal responsibility for the new application of Miraluma.

Miraluma